Driehaus Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Driehaus Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-518,754	Closed	-$6.06M	–	456
2025 Q3	$6.06M	Buy	+518,754	New	+$6.2M	0.04%	318
2021 Q1	–	Sell	-839,905	Closed	-$17.4M	–	490
2020 Q4	$17.4M	Buy	+839,905	New	+$12.5M	0.28%	112
2016 Q1	–	Sell	-41,345	Closed	-$387K	–	616
2015 Q4	$387K	Sell	41,345 -146,788	-78%	-$1.58M	0.01%	471
2015 Q3	$2.65M	Sell	188,133 -147,365	-44%	-$2.96M	0.1%	227
2015 Q2	$7.06M	Buy	+335,498	New	+$8.31M	0.24%	93

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Driehaus Capital Management's OCUL Position: Q4 2025 in Review

Driehaus Capital Management sold out of Ocular Therapeutix (OCUL) in Q4 2025, closing a stake of 518,754 shares — an estimated $6.06M sold.

Driehaus Capital Management first reported a position in OCUL in Q2 2015 and held it in 5 quarters. The position peaked at $17.4M in Q4 2020. 249 funds tracked by Wall St. Rank hold OCUL as of Q4 2025.

Driehaus Capital Management reported no remaining Ocular Therapeutix position as of Q4 2025 after selling out during the quarter.
Driehaus Capital Management sold 518,754 Ocular Therapeutix shares in Q4 2025, an estimated $6.06M.
Driehaus Capital Management first reported a position in Ocular Therapeutix in Q2 2015 and held it in 5 quarters.
Driehaus Capital Management's Ocular Therapeutix position peaked at $17.4M in Q4 2020.
249 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2025.

Based on Driehaus Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.